FDA OKs Sangamo’s IND for gene therapy candidate for hemophilia A; shares ahead 7% premarket – Seeking Alpha
Community Financial News |
FDA OKs Sangamo's IND for gene therapy candidate for hemophilia A; shares ahead 7% premarket
Seeking Alpha The FDA clears Sangamo BioSciences' (NASDAQ:SGMO) Investigational New Drug (IND) application for gene therapy candidate SB-525 for the treatment of hemophilia A. Phase 1 development to assess safety, tolerability and potential efficacy may now … Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy … |
